RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Fosun Pharma announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary. At the same time, the company will withdraw its application for a listing on China’s Third Board, the National Equities Exchange and Quotations System. Founded in 2010, Henlius is a joint venture between Fosun Pharma and US-based Henlius; Fosun owns 60% of the JV. The company was established to develop mAb biosimilar drugs, bio-betters and novel mAbs.
Source: China Biotoday
